Weekly Recap: Asundexian targets over €1 billion in U.S. sales and SUNHARBO U.S. shipments expected in November
Bayer AG (BAYN) aims for over €1 billion in U.S. sales with asundexian, targeting peak annual revenue. U.S. shipments of SUNHARBO are expected in mid-to-late November 2026, following China's approval. EU and Japan reviews are ongoing.
How this was made

The 30-second read
Why it matters
The U.S. launch and €1 billion sales target represent a significant growth opportunity for Bayer, likely prompting analyst upgrades and share price appreciation.
Market read
First‑report of a major U.S. drug launch with a high sales target, offering a clear trading catalyst for Bayer.
What to watch
Potential competition from existing anticoagulants and the need for successful market adoption in the U.S.
Background
Bayer AG (XETR:BAYN) is a German multinational pharmaceutical and life‑sciences company. Asundexian is an oral anticoagulant under development.
Ticker impact
Bayer AG announced plans to market asundexian directly in the U.S. with a target of over €1 billion in annual sales and expects SUNHARBO shipments to begin mid‑to‑late November 2026.
likely upward pressure as investors price in the billion‑euro sales potential.
The announcement is a fresh, material development for Bayer with a sizable revenue upside, suggesting a bullish reaction.
Market effects
Could boost the broader pharmaceutical and biotech sector as a new blockbuster drug enters the U.S. market.
May lift European pharma stocks, especially German exporters.
Adds to global drug pipeline optimism, potentially influencing global health‑care indices.
Counterpoint
If regulatory or reimbursement hurdles arise, the sales target may be overly optimistic, limiting upside.
Key entities
- companyBayer AG
German pharma giant planning U.S. launch of asundexian.
- productAsundexian
Oral anticoagulant drug targeting a billion‑euro market.
